Clinical trial
A Prospective, Open Label, Non-randomized, Single-Arm, Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA® in Treatment of Patients With Single or Multivessel Coronary Artery Disease (CAD)
NCT03284229 is registered in ClinicalTrials.gov with Spectranetics Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open Label, Non-randomized, Single-Arm, Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA® in Treatment of Patients With Single or Multivessel Coronary Artery Disease (CAD)
- Lead sponsor
- Spectranetics Corporation
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- September 20, 2017
- Completion date
- May 21, 2018
- Enrollment
- 28 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.